Content Type: Article

  • FDIC Releases Documents Related to Supervision of Crypto-Related Activities Amidst Signs of Shift to Deregulatory Approach to Crypto

    FDIC Releases Documents Related to Supervision of Crypto-Related Activities Amidst Signs of Shift to Deregulatory Approach to Crypto

    ARTICLE / CLIENT ALERT

    FDIC Releases Documents Related to Supervision of Crypto-Related Activities Amidst Signs of Shift to Deregulatory Approach to Crypto

    February 7, 2025

    Read time: 4 min

    Key takeaways
    Overview

    On Feb. 5, 2025, the Federal Deposit Insurance Corporation (“FDIC”) released a set of 175 documents[1] related to the FDIC’s supervision of banks that engaged in, or sought to engage in activities related to cryptocurrency or digital assets (broadly, “crypto”). In an accompanying statement, Acting FDIC Chairman Travis Hill stated, “The documents that we are releasing today show that requests [to pursue “crypto- or blockchain-related activities”] from … banks were almost universally met with resistance [from the FDIC] … Looking forward, we are actively reevaluating our supervisory approach to crypto-related activities.”[2] He also stated that the FDIC is considering replacing its 2022 letter, which required any FDIC-supervised institution to notify them of any existing or planned crypto-related activity to allow the FDIC to provide supervisory feedback.[3] Overall, the document release accompanied by Acting Chairman Hill’s statement is demonstrative of the Trump administration’s broader deregulatory stance and a potential shift at the FDIC to end debanking practices relating to crypto.

    Background

    On Jan. 3, 2025, the FDIC released 25 ‘pause letters’ in which the FDIC to various extents either instructed certain FDIC-supervised institutions to pause or not further expand certain crypto-related activities or the FDIC requested further information regarding an FDIC-supervised institution’s crypto-related activit(ies).[4] This release of the ‘pause letters’ occurred in connection with a Freedom of Information Act (“FOIA”) lawsuit by a consultant of Coinbase alleging that the agency withheld crucial documents that were responsive to a FOIA request.[5] The further release of the 175 documents on February 5 is in connection with the same lawsuit and subject matter.

    The document release on February 5 occurred on the same day as the US Senate Committee on Banking, Housing and Urban Affairs conducted a hearing on ‘debanking’ (when a bank closes or will not open an account for a customer), where at the hearing the CEO of the (only) federally-charted crypto bank, Anchorage Digital, testified that certain of Anchorage Digital’s banking relationships were terminated or prevented due to regulatory pressure because of regulators’ skepticism of or hostility to crypto-related activities.[6]

    Key Takeaways

    The document release in connection with Acting FDIC Chairman Hill’s critical views of the FDIC’s “resistance” to requests from supervised institutions to engage in crypto-related activities[7] signals that the FDIC may be shifting towards a more crypto-friendly approach consistent with the position that the Trump administration is taking.

    Acting Chairman Hill’s statement also states that the FDIC intends to replace its directive to FDIC-supervised institutions to notify the FDIC of any crypto-related activities the institutions is engaged in or plans to engage in.[8] However, this directive has not yet been replaced, and FDIC-supervised institutions should in the meantime continue to comply with its notification requirements.

    Schulte Roth & Zabel’s lawyers are available to assist you in addressing any questions you may have regarding these developments. Please contact the Schulte Roth & Zabel lawyer with whom you usually work, or any of the following attorneys:

    Donald J. Mosher – New York (+1 212.756.2187)

    Kara A. Kuchar – New York (+1 212.756.2734)

    Betty Santangelo – New York (+1 212.756.2587)

    Melissa G.R. Goldstein – Washington, DC (+1 202.729.7471)

    Adam J. Barazani – New York (+1 212.756.2519)

    Jessica Romano – New York (+1 212.756.2205)

    Jesse Weissman – New York (+1 212.756.2460)

    Julianna R. Pasquarello – New York (+1 212.756.2055)

    Jonice Q. Jackson – Washington, DC (+1 202.729.7479


    [1] View the documents.

    [2] The accompanying statement (the “Statement”) is available here.

    [3] View the 2022 letter.

    [4] View the released ‘pause letters.’

    [5] The Statement refers to the “court-ordered deadline” to release such documents by Feb. 7, 2025.

    [6] View the testimony.

    [7] Statement.

    [8] Statement.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Donald J. Mosher

    Partner

    New York – 919 Third Avenue

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Adam J. Barazani

    Partner

    New York – 919 Third Avenue

    Julianna R. Pasquarello

    Associate

    New York – 919 Third Avenue

    Jonice Q. Jackson

    Associate

    Washington, DC

    More insights

  • Key Considerations for Alcohol Suppliers in M&A Transactions

    Key Considerations for Alcohol Suppliers in M&A Transactions

    ARTICLE / CLIENT ALERT

    Key Considerations for Alcohol Suppliers in M&A Transactions

    February 6, 2025

    Read time: 11 min

    Key takeaways
    Overview

    As one of the most heavily regulated sectors in the United States, almost no aspect of the alcohol industry is untouched by regulatory considerations, including mergers and acquisitions (M&A). Whether it is a venture investment, partial- to full-ownership acquisition of an alcohol beverage company, or a divestiture, all are subject to rigorous regulatory scrutiny and requirements that need to be considered alongside traditional corporate and tax considerations.

    In this client alert, McDermott’s alcohol team provides a roadmap for M&A activity in the alcohol industry, whether businesses and investors are buying or selling alcohol companies or brands, or alcohol beverage companies are expanding into newer innovations in the non-alcoholic and never-alcoholic space.

    In depth

    The Basics

    In our experience, many lawyers struggle to appreciate the host of regulatory obligations inherent to an alcohol beverage business – obligations that can make it challenging, if not impossible, for certain parties to achieve their original intentions. Below are recurring considerations to keep top of mind when buying and selling alcohol beverage companies.

    Where Is the Company Licensed?

    One of the first considerations in understanding the regulatory environment for any alcohol industry M&A transaction is the location of the company. Each state, as well as the federal government, has its own rules and regulations regarding who must be qualified and vetted as a new owner or investor of an alcohol company, and how far their regulatory requirements, such as “tied house” laws, extend.

    For example, certain states require onerous and extensive background checks for any company and/or individual who holds any (yes, any) indirect interest in an alcohol beverage company. Other states may only vet those persons more directly involved in the direct ownership of the licensed entity or who serve as the alcohol beverage company’s officers or directors.

    What Is Happening to the Original Licensed Entity?

    While there may be a host of primarily corporate and tax considerations for fashioning a deal as an asset versus a stock purchase or – as a second example – changing the corporate form of certain of the preexisting entities from S corporations to limited liability companies (LLCs), any changes to the alcohol licensed entity and/or its direct ownership can have additional, significant consequences for the ongoing operations of the company.

    Among other potential issues, under federal law, the Alcohol and Tobacco Tax and Trade Bureau (TTB) distinguishes between a “change of control” and a “change of proprietorship,” explaining that “a change of proprietorship occurs when there is a change in the entity which owns and operates the business,” including “a change of entity type.” This is a significant distinction because, while a change in ownership allows operations to continue post-closing so long as the TTB is notified within 30 days, a change in proprietorship must be approved in advance of any close. Similar requirements and distinctions exist at the state level, with their own nuances.

    Further, because in some states it can take months to obtain approval of the new licenses, many clients need to work through interim agreements, such as transitional services agreements, to allow operations to continue in the interviewing period. The extent, availability, and structure of these agreements is important, especially since one universal principal of alcohol beverage law is that no entity other than the licensed entity may benefit from the sale of alcoholic beverages and other privileges associated with holding an alcohol license.

    How Compliant Is the Target?

    Ensuring that the seller’s “housekeeping” is in order early in the diligence process is critical to avoiding hidden financial penalties and costly administrative actions that could either put the deal in jeopardy or create significant financial burdens post-closing.

    For example, one of the most common issues we find in conducting diligence is a target’s failure to pay excise taxes in a timely manner and/or at the appropriate tax rate. Each year, the TTB’s Tax Audit Division issues a number of tax-related citations for failure to timely file and/or pay taxes (which account for nearly 70% of violations) and for the use of inappropriate tax rates. The latter stem largely from the improper use of reduced tax rates under the Craft Beverage Modernization Act, among other violations.

    Another common issue involves ownership changes that are not reported to the TTB and/or various state agencies. The company’s current organizational chart should match what is on file with the TTB or the state agency. If an unreported change of control is discovered early in the diligence process, it can be remedied. Discovered afterward, it can cause significant hurdles in identifying, for the regulatory agencies, which changes were missed along the way and preclude proceeding with the most recent ownership updates.

    Do You Know What You Are Buying?

    Most sellers are naturally reluctant to turn over certain personal information or trade secrets until closer to closing. However, obtaining certain pieces of information early in the diligence process and understanding where there may be pitfalls can help the parties determine potential dealbreakers and whether any such issues can be resolved before or after closing. Nowhere is this more important than while conducting a thorough assessment of a target’s labels, formulas, and ingredients. In most instances, these are the crown jewels of any deal, so confirming – as early in the process as possible – that what you are actually buying aligns with what you believe you are buying is critical.

    Beyond the Basics

    Preparing for an alcohol industry M&A transaction requires more than just financial due diligence and preparing for leadership changes; it demands a strategic approach to the entire business operation.

    Issues Involving Potential Distributor Changes

    First, can you make a change?

    Under ordinary commercial law principles, an asset purchase would impose no obligations (other than those assumed) on the buyer to continue doing business with the seller’s distributors. A stock/equity purchase would not alter the preexisting obligations between the target company and its distributors (of course, preexisting agreements can create additional rights and obligations between the parties). However, alcohol franchise laws alter these normal commercial principles and often contain “successorship” provisions. In general, these may bind the acquirer of a brand to continue selling the newly acquired business (often on an exclusive basis) to the brand’s prior distributors.

    Franchise states can be divided into three rough categories:

    1. Those that do not impose any obligations on brand successors;
    2. Those that impose successor obligations on successors with no further provisions on successorship; and
    3. Those that impose successor obligations but provide a mechanism for changes, with compensation.

    In certain jurisdictions, a requirement of exclusivity makes for a materially different business calculus than in a jurisdiction where the supplier can “dual.” Some statutes – mostly (but not always) confined to those pertaining to beer – include a transfer mechanism. These transfer mechanisms usually permit not-for-cause termination, but also require a “fair market value” (the term used in most statutes) payment to the distributor(s) losing the brand.

    A key issue to consider is knowing which party (the new brand owner or new distributor) is made responsible, by statute, for the payment. While indemnification arrangements are common, other issues may also arise, including whether the statute requires continued distribution during the process to calculate fair market value and whether fair market value compensation is the exclusive remedy.

    Issues Involving Inventory

    Alcohol companies, particularly wine and spirits manufacturers, often have inventory in aging barrels or as finished goods. Understanding the value, shelf life, and supply chain dependencies of the inventory will be critical for determining an accurate valuation. Robust representations and warranties about aging products (such as how far back is the look-back, how the product is being aged, where it is being aged, etc.) should be addressed in the agreement.

    Looking Ahead: Considerations for 2025

    Non-Alcoholic Products

    The market for non-alcoholic (NA) brands has been a standout growth segment for a few years. NA beer is expected to build to at least 5% share of the beer category in the United States. In terms of M&A, well-known international companies (e.g., Anheuser-Busch InBev, Tilray, and Asahi) continue to acquire local breweries – or entire brand portfolios – to bolster innovation pipelines and local market share in this segment.

    However, understanding the regulatory landscape for these companies and brands is critical, as many of these products – particularly NA beer – still bear certain hallmarks and limitations inherent in their more potent counterparts. For example, NA beverages that were originally created in their alcoholic form and then dealcoholized still require all the licenses and related ownership disclosures as any other alcoholic beverage. Similarly, certain states still treat NA products in the same manner as their more potent cousins, with particular respect to sales outlets, opportunities for shipping direct to consumers, age restrictions, and other issues.

    Alcohol-Free Products

    As consumer preferences continually develop and change, we are seeing more alcohol industry members are expanding their portfolios to include new alcohol-free products (e.g., tea, energy drinks, water) to diversify their overall offerings. However, housing both NA and alcoholic products under one overall company structure does not come without its complications.

    For example, many state regulators have expressed their concerns that an alcohol company would leverage the opportunities available in the non-alcohol space (such as slotting fee payments) for the inappropriate benefit of their alcohol brands. In fact, many alcohol state regulations apply their trade practice restrictions to industry members, regardless of whether the product in question is in fact alcoholic or NA. For this reason, we suggest that industry members considering bringing these products into their portfolios try to maintain, as much as practically possible, operational, sales, and financial separation to help mitigate regulators’ concerns of leveraging one side of the business against the other.

    Other questions that could also come into play in this space and should be considered in the context of an M&A transaction include:

    1. Would the new brands be covered under the current distribution agreement or subject to franchise law?
    2. Must the products be registered with the state?
    3. What are the reporting and compliance requirements for these products?

    “Ready-to-Drink” and Low-Alcohol Products

    Another industry trend to watch, with respect to M&A activity in 2025, is the continued growth of products containing lower amounts of alcohol. This includes canned cocktails or “ready-to-drink” beverages that tend to be spirits-based but have lower alcohol by volume (ABV) than their traditional counterparts. As noted with the products listed above, these products have their own unique regulatory considerations, including:

    1. Whether the product is governed chiefly by the TTB or the US Food and Drug Administration (as in the case of wines below 7% ABV).
    2. Whether state laws provide for unique differences for these products’ route-to-market and distribution partners, given their lower ABV.
    3. Which type of distributor – i.e., a primarily spirits or beer distributor – is best suited to support these brands, and which principles of franchise law and/or contract terms apply.

    Hemp and Low-Dose Tetrahydrocannabinol (THC) Beverages

    Finally, while technically not alcoholic beverages, it appears that hemp and low-dose THC beverages are here to stay. Federally, the 2018 Farm Bill has been extended through 2025, which means that manufacturers have another year to gain access to the hemp and intoxicating hemp beverage market before Congress potentially acts.

    For alcohol beverage companies looking to diversify into this rapidly growing – but equally rapidly shifting – market, several key considerations will be critical, including a company’s risk tolerance for products that may or may not be legal at the state level, but remain (at least on the books) illegal under federal law. Other considerations to note include:

    1. Whether you are planning to manufacture the product yourself.
    2. Whether you are you engaging a contract manufacturer.
    3. The flow of the product.
    4. The physical location where infusion of the cannabis will take place.
    5. Any potential impacts to existing alcohol licenses
    6. Plans for distribution.
    7. Plans for addressing multiples in distribution agreements.

    Conclusion


    While M&A activity in the alcohol space may continue to shift throughout 2025 and beyond as companies look to chase new opportunities and market share, consideration should always be given to the regulatory environment and its impact on realizing these new expanded opportunities and balancing the restrictions inherent of this market. McDermott’s alcohol team is well-versed in these issues and is here to support your next venture.

    Authors

    Alva C. Mather

    Partner

    Washington, DC

    Christine Dower

    Counsel

    Washington, DC

    More insights

  • No Digital Access Right – Trade Union Fails with Lawsuit against Adidas

    No Digital Access Right – Trade Union Fails with Lawsuit against Adidas

    ARTICLE

    No Digital Access Right – Trade Union Fails with Lawsuit against Adidas

    February 6, 2025

    Read time: 2 min

    Key takeaways
    Overview

    The HR News blog provides regular updates on recent developments in German employment law (in German). The latest blog post provides insights on “No Digital Access Right – Trade Union Fails with Lawsuit against Adidas”.

    Visit the blog and/or register now for regular HR NEWS updates (in German).

    In depth
    Authors

    Janek Joosten

    Associate

    Düsseldorf

    More insights

  • Securities Lending Update: SEC Approves Securities Lending Rules

    Securities Lending Update: SEC Approves Securities Lending Rules

    ARTICLE / CLIENT ALERT

    Securities Lending Update: SEC Approves Securities Lending Rules

    February 5, 2025

    Read time: 19 min

    Key takeaways
    Overview

    Executive Summary

    On Jan. 2, 2025, the US Securities and Exchange Commission (“SEC”) approved the Financial Industry Regulatory Authority, Inc.’s (“FINRA”) proposed new Rule 6500 Series (Securities Lending and Transparency Engine (“SLATE”)).[1] The SEC’s approval of the FINRA Rule 6500 Series (“SLATE Rules”)[2] represents one of the final steps in implementing (“Rule 10c-1a”) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).[3]

    FINRA’s rulemaking was mandated by Rule 10c-1a.[4] Importantly, Rule 10c-1a applies to any “covered person” or “reporting agent” (collectively, “Reporting Persons”), as such terms are defined therein, a group that includes registered broker-dealers, registered investment advisers, private funds, agent banks and registered clearing agencies and foreign (non-US) persons.[5] While only FINRA members (a group that is limited to broker-dealers registered with the SEC pursuant to Section 15 of the Exchange Act) are directly subject to FINRA rules, Rule 10c-1a requires that all Reporting Persons comply with the SLATE Rules.[6] FINRA anticipates referring potential violations of the SLATE Rules by registered investment advisers and other non-FINRA members to the SEC. Accordingly, to protect against potential SEC enforcement investigations, registered investment advisers and private funds will need to comply with the SLATE Rules, as will broker-dealers directly subject to FINRA rules.

    Rule 10c-1a and the SLATE Rules require daily same-day reporting to SLATE. FINRA will then publicly disseminate on T+1 both individual loan information and aggregated loan size information. This information, when coupled with the SEC’s monthly public dissemination of Form SHO information, will materially impact the amount of publicly available information relating to short selling activity.[7]

    Reporting to SLATE is scheduled to commence on Jan. 2, 2026, although a legal challenge regarding Rule 10c-1a is currently pending.[8] While it is difficult to assess the likely outcome of this litigation, oral arguments were heard in October 2024 and the litigation is expected to be resolved in the next few months. Even if the industry litigation is successful, Section 984(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act (‘‘Dodd-Frank Act’’) mandates that the SEC increase transparency of securities lending information available to brokers, dealers and investors. Accordingly, if successful in their litigation, industry groups will presumably press the SEC to propose and adopt less onerous securities lending rules.

    Relevant Background

    As further discussed in Schulte’s Nov. 7, 2023, Alert,[9] on Oct. 13, 2023, the SEC adopted Rule 10c-1a,[10] which requires that Reporting Persons report each “Covered Securities Loan”[11] to FINRA[12] on the day on which the loan is entered into or modified. Rule 10c-1a separately mandates that FINRA make certain information regarding Covered Securities Loans publicly available by no later than the morning of the business day after the Covered Securities Loan was reported to FINRA, including (i) information regarding individual Covered Securities Loans and (ii) aggregate transaction activity, including the distribution of loan rates for each reportable security.[13]

    As further discussed in Schulte’s Jun. 12, 2024, Alert,[14] FINRA initially proposed the SLATE Rules on May 7, 2024.[15] A number of commenters stated that FINRA’s initial proposal exceeded FINRA’s mandate under Rule 10c-1a and that, among other things, such an expansion of Rule 10c-1a’s reporting requirements would require a cost-benefit analysis, as mandated for federal agency rulemaking.[16]

    FINRA filed a partial amendment to the original proposal, which was published by the SEC on Nov. 15, 2024,[17] and eliminated most of the provisions cited by commenters as having exceeded FINRA’s rulemaking mandate. The SLATE Adopting Release approves the SLATE Rules as modified by the Partial Amendment.

    While reporting to SLATE will not commence until Jan. 2, 2026, Reporting Persons should familiarize themselves with the SLATE Rules to ensure they have sufficient time to develop systems and processes to permit timely and accurate reporting to SLATE.

    Reporting Persons Reporting Requirements

    Under the SLATE Rules, Reporting Persons will need to report extensive information about Covered Securities Loans to SLATE on a loan-by-loan basis.

    Certain information reported to SLATE, including the date and time at which the Covered Securities Loan was effected, the size of the loan, type of collateral, the rebate rate or fee (as applicable) and whether the borrower is a broker-dealer, customer (if the person lending securities is a broker-dealer), clearing agency, bank, custodian or other person, will be publicly disseminated by FINRA on a loan-by-loan basis (the “Public Data Elements”).[18]

    Other information reported to SLATE, including, where known, the legal name of each party to the covered securities loan (other than the customer from whom a broker-dealer borrows fully paid or excess margin securities), whether each party to the Covered Securities Loan is the lender, the borrower or an intermediary between the lender and the borrower (if known), whether the security is loaned from the broker’s or dealer’s securities inventory to a customer of such broker-dealer and, if known, whether the Covered Securities Loan is being used to close out a fail-to-deliver position pursuant to Rule 204 of Regulation SHO or to close out a fail-to-deliver position outside of Regulation SHO, will not be publicly disseminated (the “Confidential Data Elements”).[19]

    Loans agreed to prior to 7:00:00 p.m. Eastern Time (“ET”) must be reported to SLATE by 11:59:59 p.m. ET that business day. For loans effected on a business day after 7:00:00 p.m. ET, reporting must occur no later than 11:59:59 p.m. ET on the next business day. Loans effected on a Saturday, a Sunday, a federal or religious holiday, or other day on which SLATE is not open at any time during that day, must be reported by 11:59:59 p.m. ET on the next business day. Loan modifications must be reported on the same timeline.[20]

    Daily Public Dissemination by FINRA

    FINRA will publish both individual and aggregated loan data on a daily basis. FINRA’s public dissemination of loan data will include:

    • next-day loan-level data dissemination of the Public Data Elements other than loan size for individual covered securities loans;
    • T+20 dissemination of the loan size for individual Covered Securities Loans and
    • aggregate loan activity and distribution of loan rates for Covered Securities Loans.[21]

    Aggregate loan activity will include the “aggregate volume of securities” subject to an initial Covered Securities Loan or a modification to the amount of securities loaned reported on the prior business day.[22] To help avoid information leakage, FINRA has adopted a de minimis exception whereby aggregate loan activity will not be published unless reports for at least ten (10) distinct Covered Securities Loans were submitted to SLATE on the prior business day.[23]

    Aggregated Loan Data and Distribution of Loan Rates

    For aggregate loan data, FINRA will disseminate the aggregate volume of securities both in total and broken down by collateral type (i.e., cash collateral and non-cash collateral).[24]

    The distribution of loan rates will separately be provided for (x) loans collateralized by cash and (y) loans not collateralized by cash.[25] For loans and modifications collateralized by cash, the highest rebate rate, lowest rebate rate and volume-weighted average of the rebate rates by US currency and non-US currency will be published.[26] For loans and modifications not collateralized by cash, FINRA will publish the highest lending fee or rate, lowest lending fee or rate and volume-weighted average of the lending fees or rates reported to SLATE.[27]

    Material Changes from the Original SLATE Proposal

    The SLATE Rules, as adopted, includes a number of welcome changes compared to the SLATE Rules as initially proposed.

    Deletion of Certain Data Elements. As proposed, the SLATE Rules would have required that Reporting Persons report to SLATE certain data elements that are not required by Rule 10c-1a, including: (1) the expected settlement date of the Covered Securities Loan or modification; (2) “any other fees or charges” (i.e., the dollar cost of any other fees or charges in addition to the rebate rate or securities lending fee, which would have separately been reported); (3) whether the covered person is the lender, borrower or intermediary; (4) if the Covered Securities Loan is an allocation of an omnibus loan effected pursuant to an agency lending agreement, the unique internal identifier for the associated omnibus loan assigned by the Reporting Persons responsible for reporting the Covered Securities Loan to SLATE; (5) such modifiers and indicators otherwise required by the SLATE Rules or the SLATE specifications; and (6) the unique internal identifier assigned to the Covered Securities Loan by the Reporting Persons responsible for reporting the loan to SLATE.

    Commenters expressed concerns that the reporting and public dissemination of information not mandated by Rule 10c-1a exceeded FINRA’s authority and increased the risk of information leakage.[28] As noted above, FINRA, in determining not to adopt such requirements, acknowledged commenters’ concerns, although it indicated that it did not agree with commenters’ views that it had exceeded its authority to adopt such requirements.[29]

    Increased reporting time. As originally proposed, Reporting Persons would have been required to report each covered securities loan entered into between 12:00:00 a.m. and 7:45:00 p.m. to SLATE by no later than 8:00:00 p.m. (all times ET). Accordingly, Reporting Persons could have been subject to reporting windows as short as fifteen (15) minutes.

    As adopted, Reporting Persons will need to report each covered securities loan entered into between 12:00:00 a.m. and 7:00:00 p.m. to SLATE by no later than 11:59:59 p.m. (all times ET). This should help alleviate commenters’ concerns, particularly as it relates to loans agreed to after the close of regular trading hours.

    Reporting of Loan Rates. As originally proposed, where a fee or rebate was calculated as a spread to a reference rate or other benchmark, Reporting Persons would have been required to report the effective (calculated) loan rate. Accordingly, Reporting Persons would have been required to submit a modification whenever there was a change in the value of the reference rate.

    In response to commenters’ concerns, Reporting Persons may now report:

    • the rebate rate or lending fee or rate as of the date the Covered Securities Loan was effected;
    • the identity of the benchmark or reference rate; and
    • the spread.

    The ability to report a reference rate and agreed to spread (along with the effective rate on the day on which the loan was effected) should ease reporting burdens.

    If preferred, Reporting Persons may instead report the effective rate, although they would be required to submit modification reports for any change in the effective rate. As further discussed below, FINRA’s proposed fee schedule will assess a fee for each modification report submitted to SLATE; as such, we assume most (if not all) Reporting Persons will elect to report the benchmark rate and spread (and such other required information) to avoid such additional costs.

    Open Questions

    While the adoption of final SLATE Rules provides some clarity to Reporting Persons, a number of open questions remain, including what constitutes a “loan” for purposes of Rule 10c-1a and the SLATE Rules, the jurisdictional scope of Rule 10c-1a (and, as such, the SLATE Rules) and FINRA’s authority to adopt reporting requirements not clearly contemplated by Rule 10c-1a and, separately, disseminate information regarding covered securities loans in a manner not contemplated by Rule 10c-1a.

    What is a “Loan”? Commenters requested additional guidance regarding what constitutes a “loan” for purposes of Rule 10c-1a and the SLATE Rules.[30] FINRA noted that whether a particular transaction is a loan is “an issue that is not related to determinations that FINRA has made regarding the proposed reporting requirements or dissemination provisions of SLATE,” and pointed commenters to the Rule 10c-1a Adopting Release.[31] However, the Rule 10c-1a Adopting Release provides limited guidance regarding the term, noting that it typically requires a facts-and-circumstances assessment.[32]

    Jurisdictional Scope. In adopting Rule 10c-1a, the SEC provided limited guidance regarding the jurisdictional scope of Rule 10c-1a, only noting that reporting was triggered where a covered securities loan was “effect[ed], accept[ed], or facilitate[d] (in whole or in part) in the US.”[33] The SEC, in approving the SLATE Rules, did not provide any additional context regarding these terms. However, FINRA indicated that foreign securities that have not, at the time of the loan, otherwise been reported to CAT may nevertheless be “reportable securities,”[34] and, as such, loans in such securities may represent “covered securities loan” if “effect[ed], accept[ed], or facilitate[d] (in whole or in part) in the US.” While we highlighted this potential issue in our Nov. 7, 2023, Alert,[35] FINRA’s “clarity” will likely increase concerns and confusion regarding Rule 10c-1a’s extraterritorial scope.

    FINRA Authority. While the SLATE Rules, as adopted, walked back a number of the provisions that commenters viewed as exceeding Rule 10c-1a’s mandate,[36] the extent of FINRA’s authority regarding the SLATE rulemaking and related requirements remains unclear. For instance, FINRA did not acknowledge any limitations on its authority to adopt reporting requirements that exceeded Rule 10c-1a’s express mandate; rather, FINRA noted that its decision to remove the provisions cited by commenters was done to ensure the SLATE Rules were adopted within the time frame established by the SEC.[37] Accordingly, FINRA could attempt to adopt some or all of the removed provisions, or other provisions not plainly contemplated by Rule 10c-1a, in the future.

    Recent Executive Order and New SEC Administration. President Donald Trump issued an Executive Order, “Regulatory Freeze Pending Review.” While the Executive Order requests that agencies consider postponing the “effective date” of rules that have yet to take effect, the effective date of Rule 10c-1a was Jan. 2, 2024. Notwithstanding Rule 10c-1a’s effective date preceding the Executive Order, there is an ongoing industry litigation aiming to vacate Rule 10c-1a and Exchange Act rule 13f-2 (which requires reporting on Form SHO) which may be successful. Further, as Rule 10c-1a’s compliance date is not until Jan. 2, 2026, the SEC may take other actions in the interim that impact Rule 10c-1a, although it is unclear what such actions would entail and whether Rule 10c-1a is currently on the SEC’s radar.

    SLATE Fees – Proposed Rulemaking

    On Nov. 21, 2024, FINRA proposed to establish new FINRA rule 7720, which would establish fees for: (1) SLATE system connectivity; (2) initial Covered Securities Loan reporting; (3) loan modification reporting; (4) late reporting; and (5) reporting cancellations, corrections and deletions (collectively, the “SLATE Reporting Fees”)[38]. Rule 7720 would also establish fees for access to certain SLATE loan-level data (i.e., data regarding individual covered securities loans reported to SLATE) and SLATE daily loan statistics (i.e., aggregate loan information published by SLATE, including information regarding the distribution of loan rates)and historic SLATE data (collectively, the “SLATE Data Access Fees”).

    SLATE Reporting Fees. Under the SLATE Fee Proposal, the following reporting “fees” would apply.

    • Initial Covered Securities Loan Reporting. SLATE Participants will be subject to a fee of $0.07 per submission.
    • Loan Modification Reporting. SLATE Participants will be subject to a fee of $0.03 per modification submission.
    • Late Reporting. SLATE Participants will be assessed a late fee of $0.20 for each covered securities loan report that is not timely reported to SLATE as required under the SLATE Rules. This, effectively, would act as a penalty for late reporting.
    • Cancellations, Corrections and Deletions. SLATE Participants will be assessed a fee of $0.10 for each canceled, corrected or deleted Covered Securities Loan report.

    Accordingly, each Covered Securities Loan will be subject to a minimum fee of $0.10 (that is, each initial report will incur a fee of $0.07 and each loan will require at least one modification in connection with its termination (and an associated $0.03 fee), even if terminated in accordance with its terms).

    Additionally, FINRA will charge a $25 monthly fee, assessed at the User ID level, to connect to SLATE for reporting purposes. SLATE Participants using a third-party reporting intermediary will not be directly subject to such monthly fee.

    SLATE Data Access Fees. Under the SLATE Fee Proposal, the following would be charged to access SLATE loan-level data, SLATE daily loan statistics and historic SLATE data.

    • SLATE Loan-Level Data and SLATE Daily Loan Statistics – Internal Use. $3,000 per month. While such data “is enabled for unlimited internal use through any number of display applications,”[39] “bulk redistribution” is prohibited,[40] although the SLATE Fee Proposal does not clearly define what “bulk redistribution” would entail.
    • SLATE Loan-Level Data and SLATE Daily Loan Statistics – Vendor Display Redistribution Fee. $10,000 per month. Notably, bulk redistribution is also prohibited under this subscription although, as noted above, the SLATE Fee Proposal does not clearly define what “bulk redistribution” would entail.
    • Historic SLATE Data.[41] A one-time single fee of $2,000 for development and set-up, ongoing fees of $5,000 per calendar year.

    Persons wishing to subscribe to any of the above data offerings will be required to enter into agreements with FINRA, although FINRA will separately make the SLATE loan-level data and SLATE daily loan statistics available free of charge on its website for personal, non-commercial purposes.[42] Further, certain tax-exempt organizations will be subject to fees that are half those of charged to other subscribers.[43]

    Conclusion

    Reporting Persons and other interested parties should review FINRA’s SLATE Rules, Partial Amendment No. 1 and the SEC’s Notice adopting the SLATE Rules.[44] Absent a ruling favorable to industry groups in the current litigation,[45] Reporting Persons must begin reporting Rule 10c-1a information to FINRA starting on Jan. 2, 2026. FINRA will begin publicly reporting Rule 10c-1a information daily on April 02, 2026.

    Authored by William Barbera, Marc Elovitz, Kelly Koscuiszka, Derek Lacarrubba and Kris Kendall.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] Order Approving a Proposed Rule Change, as Modified by Partial Amendment No. 1, To Adopt the FINRA Rule 6500 Series (Securities Lending and Transparency Engine (SLATETM)), Release No. 34-102093 (90 Fed. Reg. 1563) (Jan. 8, 2025) (“SLATE Adopting Release”) available here.

    [2] Notice of Filing of a Proposed Rule Change to Adopt the FINRA Rule 6500 Series (Securities Lending and Transparency Engine (SLATE™)), Release No. 34-100046 (89 Fed. Reg. 38203) (May 7, 2024) (“FINRA Proposal”) available here.

    [3] FINRA’s proposed fee schedule for SLATE participants and market participants wishing to use SLATE data awaits approval (“SLATE Participants”). FINRA’s proposed rulemaking is discussed herein.

    [4] Reporting of Securities Loans, 88 Fed. Reg. 75644 (Nov. 3, 2023), (“10c-1a Adopting Release”) available here.

    [5] A “covered person” is defined in Rule 10c-1a(j)(1) as: “(i) [a]ny person that agrees to a covered securities loan on behalf of a lender (“intermediary”) other than a clearing agency when providing [certain defined services]; (ii) [a]ny person that agrees to a covered securities loan as a lender when an intermediary is not used unless [clause (iii)] applies; or (iii) [a] broker or dealer when borrowing fully paid or excess margin securities pursuant to Rule 15c3-3(b)(3) of the Exchange Act. A “reporting agent” is defined in Rule 10c-1a(j)(4) as “a broker, dealer, or registered clearing agency that enters into a written agreement with a covered person under paragraph (a)(2) of this section.”

    [6] See, e.g., Rule 10c-1a(a)(1), noting that covered persons must “[p]rovide to [FINRA] the information in paragraphs (c) through (e) of [Rule 10c-1a] (“Rule 10c-1a information”), in the format and manner required by the applicable rule(s) of [FINRA]…”

    [7] That is, as the majority of short sales are settled with borrowed securities. Separately, while subject to ongoing litigation and potential SEC action delaying the compliance date, public dissemination of aggregated and anonymized Form SHO data is scheduled to commence in April 2025 and will thereafter occur approximately one month after the end of the month for which short positions are reported (e.g., reports reflecting short positions from June 2025 will be reported by the end of July 2025).

    [8] The National Association of Private Fund Managers, the Alternative Investment Management Association, and the Managed Funds Association have filed a lawsuit in the US Court of Appeals for the Fifth Circuit seeking to invalidate Rule 10c-1a (Nat’l Assoc. Priv. Fund Mgr. v. SEC, No. 23-60626 (5th Cir.)). This lawsuit is ongoing as of the date of this publication.  The petition for review can be found here.

    [9] See Schulte’s Nov. 7, 2023, Alert, available here.

    [10] 10c-1a Adopting Release.

    [11] See Rule 10c-1a(j)(2). Subject to certain exceptions, a covered securities loan is defined as “[a] transaction in which any person on behalf of itself or one or more other persons, lends a reportable security to another person.” A reportable security is defined under Rule 10c-1a(j)(3) as “any security or class of an issuer’s securities for which information is reported or required to be reported to the consolidated audit trail as required by § 242.613 of the Exchange Act and the CAT NMS Plan (“CAT”), the Financial Industry Regulatory Authority’s Trade Reporting and Compliance Engine,or the Municipal Securities Rulemaking Board’s Real-Time Transaction Reporting System,or any reporting system that replaces one of these systems.”

    [12] These reports are made to FINRA in its capacity as the current sole registered national securities association.

    [13] See Schulte’s previous Alert regarding the substance of Rule 10c-1a, available here.

    [14] See Schulte’s Jun. 12, 2024, Alert, available here.

    [15] See FINRA Proposal, available here.

    [16] See SLATE Adopting Release at 28, fn. 111 (referencing ISLA Americas Letter 1, at 4–5; SIFMA AMG Letter 2, at 7–8; and Hagerty Letter, at 1–3).

    [17] See Securities Exchange Act Release No. 101645 (Nov. 15, 2024), 89 FR 92228 (Nov. 21, 2024) (“Partial Amendment”), available here.

    [18] See FINRA Rule 6530(a)(2)(A) through (L) for a list of all Public Data Elements. As further discussed herein, loan size for individual covered securities loans will be disseminated on a delayed (T+20) basis, although information regarding aggregate loan size for each reportable security underlying Covered Securities Loans reported on the prior day will be disseminated on T+1.

    [19] See FINRA Rule 6530(a)(2)(M) through (U) for a list of all Confidential Data Elements.

    [20] Loan modifications are changes to any data element with respect to a covered securities loan. See SLATE Adopting Release at 9.

    [21] See SLATE Adopting Release at 15.

    [22] See SLATE Adopting Release at 17.

    [23] See FINRA Rule 6540, Supplementary Material .01 (“notwithstanding paragraph (c)(1) of this Rule, FINRA will not include aggregate volume information for a Reportable Security unless there were reports submitted to SLATE on the prior business day for at least ten distinct Covered Securities Loans in the Reportable Security (represented by different FINRA-assigned unique loan identifiers”).

    [24] See SLATE Adopting Release at 19.

    [25] See FINRA Rule 6540(c)(2).

    [26] See FINRA Rule 6540(c)(2).

    [27] See FINRA Rule 6540(c)(2).

    [28] See Partial Amendment at 92229.

    [29] See Partial Amendment at 92232.

    [30] See SLATE Adopting Release at 58.

    [31] See SLATE Adopting Release at 58.

    [32] See Rule 10c-1a Adopting Release at 85.

    [33] See Rule 10c-1a Adopting Release at 165 (discussing jurisdictional triggers for Rule 10c-1a reporting requirements).

    [34] FINRA noted that covered persons would need to apply for a security identifier in such instances.  See SLATE Adopting Release at 60-61.

    [35] Available at /insights/sec-securities-lending-rule-increased-transparency-and-the-risk-of-information-leakage/.

    [36] See SEC Schulte’s previous Alert discussing the securities lending rules, available at /insights/securities-lending-update-sec-extends-review-period-for-proposed-securities-lending-rules/.

    [37] See SLATE Adopting Release at 80-81, 83.

    [38] See Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Adopt Fees in FINRA Rule 7720 (Securities Lending and Transparency Engine (SLATETM)), Release No. 34-101697 (89 Fed. Reg. 93750) (Nov. 27, 2024) (“SLATE Fee Proposal”) available here.

    [39] See SLATE Fee Proposal at 93752.

    [40] See SLATE Fee Proposal at 93752.

    [41] Defined at proposed FINRA Rule 7720(e)(1) as “SLATE Loan-Level Data and [SLATE] Daily Loan Statistics from the beginning of SLATE data reporting through the end of the most recent calendar year.”

    [42] See FINRA Rule 6540, Supplementary Material .02.

    [43] See SLATE Fee Proposal at 93753.

    [44] Registered investment advisers and private funds will need to comply with the FINRA SLATE Rules.

    [45] See footnote 7, supra.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    William J. Barbera

    Partner

    New York – 919 Third Avenue

    Marc E. Elovitz

    Partner

    New York – 919 Third Avenue

    Kelly Koscuiszka

    Partner

    New York – 919 Third Avenue

    More insights

  • Responding to Stop Work Orders Implementing Recent Executive Orders

    Responding to Stop Work Orders Implementing Recent Executive Orders

    CLIENT ALERT / US POLICY

    Responding to Stop Work Orders Implementing Recent Executive Orders

    February 4, 2025

    Read time: 9 min

    Key takeaways
    Overview

    Since the inauguration of US President Donald Trump on January 20, 2025, many companies that hold or support Federal contracts, grants, and other awards have received so-called “stop work orders” or other directives to cease certain activities in connection with their Federal work. Federal agencies have issued many of these orders and directives to prime contractors and recipients. In turn, those prime contractors and recipients have passed them onto subcontractors and subrecipients, among others.

    In depth

    On January 31 and February 3, 2025, Federal district courts in Rhode Island and the District of Columbia simplified the playbook for responding to many of these stop work orders. On January 31, the US District Court for Rhode Island issued a Temporary Restraining Order (the Rhode Island TRO) in a lawsuit filed by 23 state attorneys general challenging a January 27, 2025, memorandum issued by the Office of Management and Budget (OMB) pausing all disbursements and obligations under Federal grants, cooperative agreements, and other Federal financial assistance subject to the Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards at 2 C.F.R. Part 200 (the Uniform Guidance).

    The Rhode Island TRO directs that President Trump, OMB, and various Federal agencies named as defendants in the lawsuit “shall not pause, freeze, impede, block, cancel, or terminate [the Government’s] compliance with awards and obligations to provide federal financial assistance to the States,” and “shall not impede the States’ access to such awards and obligations, except on the basis of the applicable authorizing statutes, regulations, and terms.” The Court ordered the defendants’ lawyers to provide written notice of the TRO to all “agencies and their employees, contractors, and grantees” and to file a copy of the notice with the Court. In a filing on February 3, the defendants’ lawyers confirmed that written notice had been sent to the referenced parties on January 31, 2025, and filed a copy of that notice with the Court (the Government’s notice).

    The Rhode Island District Court found that the state attorneys general were likely to succeed on their claims that the pause in disbursements exceeds the executive branch’s authority under the US Constitution and applicable statutes. The Court ruled:

    The Executive’s action unilaterally suspends the payment of federal funds to the States and others simply by choosing to do so, no matter the authorizing or appropriating statute, the regulatory regime, or the terms of the grant itself. The Executive cites no legal authority allowing it to do so; indeed, no federal law would authorize the Executive’s unilateral action here.

    Although OMB had rescinded its January 27 memorandum on January 29, the Rhode Island District Court found that “the alleged rescission of the OMB Directive was in name only and may have been issued simply to defeat the jurisdiction of the courts. The substantive effect of the directive carries on.”

    On February 3, the US District Court for the District of Columbia issued a similar injunction (the DC TRO) in a lawsuit filed by several coalitions of nonprofit organizations. Although the Trump administration had already interpreted the Rhode Island TRO as applying to “all awards or obligations – not just those involving the Plaintiff States,” the DC TRO enjoins the implementation of the January 27 memorandum “to the maximum extent provided for by Federal Rule of Civil Procedure 65(d)(2) and 5 U.S.C. §§ 705 and 706,” the latter of which has been interpreted to authorize injunctions without party limitation. And whereas the Rhode Island TRO prohibited the Government from “imped[ing] the States’ access to awards and obligations,” the DC TRO directs the Government “to release any disbursements on open awards that were paused” because of OMB’s January 27 memorandum.

    Based on the Rhode Island and DC TROs, companies that received a stop work order invoking any of the executive orders issued by the Trump administration since January 20 should immediately seek clarification from the agency that issued the order on (1) whether and to what extend the order remains in effect, and (2) the legal basis for giving any effect to the order in the wake of the Rhode Island and DC TROs. Companies that plan to resume operations that were previously stopped or suspended should advise agencies of their plans, and companies that have identified cost impacts and disruptions from the stop work orders should advise agencies of those impacts and disruptions to the best of their ability. Companies should direct the attention of the agency that issued the order to the Rhode Island and DC TROs, as well as the Government’s notice to agencies regarding the Rhode Island TRO, which states, “Federal agencies cannot pause, freeze, impede, block, cancel, or terminate any awards or obligations on the basis of the OMB Memo, or on the basis of the President’s recently issued Executive Orders.” Although the Government’s notice was required to be disseminated to all Government “employees, contractors, and grantees by Monday, February 3, 2025, at 9 a.m.,” many companies that received stop work orders have yet to receive this notice. Companies should also follow up on all outstanding payment requests and demand payment for any amounts due. As noted above, the DC TRO expressly directs the Government “to release any disbursements on open awards that were paused” because of OMB’s January 27 memorandum.

    The Rhode Island and DC TROs arguably are limited to awards of Federal financial assistance under the Uniform Guidance, as those awards were the subject of the since-rescinded January 27 OMB memorandum that triggered the lawsuits. As such, the Rhode Island and DC TROs arguably do not directly enjoin pauses in disbursements resulting from stop work orders issued under procurement contracts subject to the Federal Acquisition Regulation (FAR) at 48 C.F.R. Parts 1-52. Although much of the reasoning behind the Rhode Island and DC TROs should also condemn similar stop work orders issued under the clause at FAR 52.242-15, Stop Work Order, companies should be aware of substantial differences between the FAR and the Uniform Guidance in this area.

    Unlike the FAR, the Uniform Guidance generally does not provide for a broad right to terminate grants, cooperative agreements, and other awards for the Government’s convenience. Rather, 2 C.F.R. 200.340(a)(4) contemplates that a Federal award may be terminated “pursuant to the terms and conditions of the Federal Award, including, to the extent authorized by law, if an award no longer effectuates the program goals or agency priorities.” The Uniform Guidance does not contemplate stop work orders or suspensions of performance at all, although some agency supplements to the Uniform Guidance do, with reference to similar language to Section 200.340. Regardless, the “program goals” and “agency priorities” referenced in Section 200.340(a)(4) are the goals and priorities established for the program at the time the grant was awarded. The regulatory history of this provision does not indicate that it was intended to provide the Government with a vehicle to unilaterally terminate – or suspend – grants because the Government no longer wishes to achieve those goals and priorities. Moreover, Section 200.340, by its terms, does not give the Government any rights, and instead directs the parties to a grant to the “terms and conditions of the Federal Award.” Individual awards may not address terminations for anything other than nonperformance or may include termination provisions that more closely resemble FAR termination for convenience clauses.

    Although the FAR provides Government agencies with a broad right to terminate contracts for the Government’s convenience, and although the FAR specifically allows the Government to stop work under a contract, the reasoning in the Rhode Island and DC TROs calls into question stop work orders issued under procurement contracts as well. Contractors that received stop work orders invoking the Trump administration’s executive orders should seek to clarify the status of those orders following the TROs. Contractors seeking to recommence performance under a stopped contract can also submit a claim under the Contract Disputes Act seeking a declaration that the stop work order is unlawful. Such a claim may be a prerequisite to further judicial review for FAR-based contracts, particularly if the contracting agency does not provide the requested clarification.

    Next Steps

    Although the Rhode Island and DC TROs should trigger the rescission of many stop work orders issued since the inauguration, more stop work orders are likely to come. The Government’s notice to agencies regarding the Rhode Island TRO emphasizes that, “Agencies may exercise their own authority to pause awards or obligations, provided agencies do so purely based on their own discretion – not as a result of the OMB Memo or the President’s Executive Orders – and provided the pause complies with all notice and procedural requirements in the award, agreement, or other instrument relating to such a pause.”

    For companies holding grants, cooperative agreements, and other awards under the Uniform Guidance, we have prepared a checklist to help companies digest and respond to stop work orders invoking the Trump administration’s executive orders, as well as stop work orders that attempt to navigate the Rhode Island and DC TROs. Companies receiving stop work orders under the FAR will spend substantially less time determining the source and scope of the government’s rights under the contract than companies receiving stop work orders ceasing performance of awards under the Uniform Guidance and can more easily determine whether to dispute a stop work order and proceed accordingly.

    McDermott’s Government Contracts Group can assist contractors and recipients in navigating this evolving landscape. For more information, reach out to the authors of this article or your regular McDermott lawyer(s).

    Authors

    Daniel P. Graham

    Partner

    Washington, DC

    Tara L. Ward

    Partner

    Washington, DC

    Llewelyn M. Engel

    Partner

    Washington, DC

    Peter M. Routh

    Associate

    Washington, DC

    Elizabeth Hummel

    Associate

    Chicago

    More insights

  • Trump Administration Places DOL’s ESOP Proposals in Regulatory Moratorium

    Trump Administration Places DOL’s ESOP Proposals in Regulatory Moratorium

    CLIENT ALERT / US POLICY

    Trump Administration Places DOL’s ESOP Proposals in Regulatory Moratorium

    February 4, 2025

    Read time: 7 min

    Key takeaways
    Overview

    On January 16, 2025, the US Department of Labor’s (DOL) Employee Benefits Security Administration (EBSA) released two pieces of guidance that, if finalized, would dramatically change the landscape for fiduciaries responsible for determining the value of stock in privately held corporations when engaging in a transaction with an employee stock ownership plan (ESOP). The first piece of guidance involves the long-awaited and highly anticipated “adequate consideration” regulations under the Employee Retirement Income Security Act of 1974 (ERISA), which apply when setting the price at which an ESOP can buy and sell stock. The second piece involves a proposed prohibited transaction exemption (PTE) that would create a safe harbor for selling shareholders and plan fiduciaries when engaging in an initial transaction with a newly established ESOP.

    On January 20, 2025, a slew of executive orders issued by the new administration froze all pending proposals from the prior administration, including the proposed regulations and the proposed PTE. Previously scheduled to be published in the Federal Register on January 22, 2025, the proposed guidance was withdrawn, and its unpublished versions were removed from the Federal Register website until new administration can review and approve – or modify in whole or in part – the proposed adequate consideration regulations and the proposed PTE.

    Given the removal of the proposed guidance from the Federal Register, the recently issued proposed regulations and PTE have no force or effect. We caution against using such information to guide current thinking on ESOP transactions.

    In depth

    Adequate Consideration Under ERISA

    Background

    The proposed adequate consideration regulations released on January 16 aimed to provide more clarity on valuing non-publicly traded employer stock acquired or sold by ESOPs in accordance with ERISA’s requirements. The acquisition or sale of qualifying employer securities is not exempt from the prohibited transaction rules under ERISA unless, among other requirements, the transaction is for adequate consideration. Current guidance (namely, the 1988 DOL proposed regulations) defines adequate consideration as a price not less favorable to the plan than the “fair market value” of the stock determined in good faith by the trustee or named fiduciary pursuant to the terms of the plan and in accordance with regulations promulgated by the DOL. Fair market value for purposes of the definition of adequate consideration is the price at which an asset would change hands between a willing buyer and a willing seller. The absence of clearer and more objective guidance regarding the definition of “adequate consideration” – other than the “I know it when I see it test” – has exposed ESOPs and their fiduciaries to expensive lawsuits over the years that challenge the valuation process or methodology used, the substantive value concluded, and/or both in ESOP transactions.

    Proposed Regulation

    The January 16 proposed regulations set forth a two-part test for adequate consideration: fair market value and a good faith determination of that value:

    1. If the employer stock is not readily tradable, fair market value generally means the price at which the employer stock would change hands in an arm’s-length transaction between a willing buyer and a willing seller when the former is not under any compulsion to buy and the latter is not under any compulsion to sell, the parties are both willing and able to trade, and have reasonable knowledge of the facts relevant to the stock’s value.
    2. Whether the fair market value has been determined in good faith entails independent plan trustees or named fiduciaries determining value in accordance with a prudent process designed to ensure a sound conclusion as to the stock’s fair market value in accordance with ERISA’s fiduciary standards of prudence and loyalty. Components of such a process include requirements that the fiduciary prudently:
      1. Select a qualified independent appraiser to prepare a written valuation report.
      2. Oversee production of a written valuation report based on complete, current, and accurate information.
      3. Review the valuation report to ensure that it may reasonably be relied upon.

    It is further noted that the preamble to the adequate consideration regulations emphasizes the need for a “prudent” and good faith process to determine if adequate consideration has been appropriately determined. Unfortunately, while purporting to focus on fiduciary process, the proposed adequate consideration regulations go further to prescribe certain absolute requirements that should, in our view, be left to the appropriate fiduciary review and process, as opposed to dictated by regulation. A deep dive into such issues is beyond the scope of this alert, but it is noted that even if reissued and finalized in their proposed form, the adequate consideration regulations are not likely to make establishing new ESOPs easier, less costly, or subject to less litigation.

    The proposed adequate consideration regulations include a revocation of the 1988 proposed rule, which was never finalized or withdrawn by the DOL. However, until reissuance of the withdrawn January 16 proposed regulations, they may not be used as the standard for review by the DOL, and fiduciaries and courts must continue – reluctantly – to rely on the 1988 proposed regulations for guidance.

    Proposed PTE Safe Harbor

    The proposed PTE establishes a safe harbor for fiduciaries buying, and shareholders (of the ESOP sponsor) selling, non-publicly traded employer stock in an initial transaction with a newly established ESOP. The safe harbor in the proposed PTE is subject to protective conditions designed to ensure that any transaction relying on the safe harbor complies with ERISA.

    Specifically, any trustee that represents the interests of the ESOP in a transaction must be independent of the employer and solely responsible for determining the appropriate transaction purchase price for the employer stock. The independent trustee may rely upon a valuation of an appraiser so long as the appraiser is independent of the employer and the independent trustee determines that the appraiser’s advice is sound, prudent, and loyal to the ESOP participants. Lastly, the independent trustee and appraiser would be able to provide to the selling shareholders certifications to verify compliance with the exemption upon which the selling shareholders would be permitted to rely.

    As drafted, the tick-list approach of the proposed PTE would almost certainly have unintended negative consequences if ultimately finalized. As drafted, such guidance clearly erodes any focus on a thoughtful, principles-based valuation process and provides a false sense of security dependent on detailed and burdensome checklist items rather than an understanding of the underlying requirements and goals of an ESOP purchase. Further transactions following such PTE “rules” may or may not actually serve to protect participants who are the intended beneficiaries of an ESOP implementation transaction. The PTE also calls into question those plan sponsors, fiduciaries, and sellers who acted in good faith under the terms of the proposed adequate consideration regulations (if issued), which would further vitiate the certainty that was sought upon the ESOP community’s clamoring for appropriate guidance in the form of regulations.

    Ultimately, the new administration must now work its way through the proposed, and now suspended, regulations and PTE issued by the prior administration to determine what, if anything, will be kept on reissuance (if any). Practitioners, in the meantime, are left with the prior, antiquated guidance and significant uncertainty. This process has underscored the need for appropriate and thoughtful regulation that will allow employers to create ESOPs to benefit employees through an almost-solely employer-provided program.

    McDermott’s employee benefits team will continue to analyze in detail both proposals, ready comments on both proposals for consideration by the new administration, and provide a detailed analysis and commentary upon their release for public inspection in the Federal Register.

    Authors

    Allison Wilkerson

    Partner

    Dallas

    Erin Turley

    Partner

    Dallas

    Myriem Bennani

    Associate

    Chicago

    More insights

  • Human Trafficking Monitoring for Telehealth Providers

    Human Trafficking Monitoring for Telehealth Providers

    ARTICLE

    Human Trafficking Monitoring for Telehealth Providers

    Feb 3, 2025

    Read time: 6 min

    Key takeaways
    Overview

    Overview: Telehealth providers are uniquely positioned to monitor for human trafficking when interacting with patients. Survivor records indicate that health services are among the most common points of access to help trafficked persons, and nearly 70% of human trafficking survivors report having had access to health services at some point during their exploitation. While there’s limited data regarding trafficked persons’ use of telehealth services, empirical evidence demonstrates that a greater proportion of trafficked persons completed telehealth appointments during the early period of the COVID-19 pandemic than pre-pandemic. To enable telehealth providers to assist trafficked patients, this article discusses the legal landscape surrounding human trafficking and lays out best practices for telehealth providers.

    Background: Telehealth providers are subject to a patchwork of legal requirements aimed at reducing human trafficking. If the patient is under the age of 18 or is disabled, many states require telehealth providers to report instances in which they know or reasonably believe the patient has experienced or is experiencing abuse, mistreatment, or neglect. Some states, such as Florida and New Jersey, also require telehealth providers partake in anti-trafficking education.

    Online platforms that offer telehealth services are also subject to federal legislation regarding sex trafficking monitoring. In 2018, US Congress passed the Allow States and Victims to Fight Online Trafficking Act of 2017 (FOSTA). The law was enacted primarily in response to unsuccessful litigation against Backpage.com, a website accused of permitting and even assisting users in posting advertisements for sex trafficking. Before FOSTA’s enactment, Section 230 of the Communications Decency Act essentially shielded online platforms from liability for such conduct. FOSTA, however, effectively created an exception to Section 230 by establishing criminal penalties for those who promote or facilitate sex trafficking through their control of online platforms. These penalties, generally limited to a fine, imprisonment of up to 10 years, or both, may be heightened for aggravated violations, which are violations involving reckless disregard of sex trafficking or the promotion or facilitation of prostitution of five or more people. State attorneys general and, in cases of aggravated violations, injured persons also may bring civil actions against those who control online platforms in violation of the law.

    Since FOSTA’s inception, the US Department of Justice (DOJ) has brought at least one criminal charge under the law. In 2021, after being charged by DOJ, the owner of the online platform CityXGuide.com pleaded guilty to one count of promotion of prostitution and reckless disregard of sex trafficking, a violation of FOSTA’s aggravated violations provision. According to DOJ officials, more charges have not been brought under FOSTA because the law is relatively new and federal prosecutors have had success prosecuting those who control online platforms by bringing racketeering and money laundering charges. Nonetheless, it is possible that prosecutors will pursue FOSTA violations more regularly during the Trump administration, particularly because US President Donald Trump signed it into law during his first term in office, calling it “crucial legislation.”

    Best Practices for Telehealth Providers

    Telehealth providers and online platforms that offer telehealth services should consider adhering to the following best practices when monitoring for human trafficking:

    • Complete Anti-Trafficking Training. Telehealth providers should complete an anti-trafficking training or educational program on a regular basis, regardless of whether they are legally required to do so. One such program is the US Department of Health and Human Services’ Stop, Observe, Ask, and Respond (SOAR) to Health and Wellness Training program. Telehealth providers may attend SOAR trainings in person or online and, depending on the program, may receive continuing education credit for their participation.
    • Implement a Referral Network. Prior to monitoring patients, telehealth providers should prepare a comprehensive referral list with detailed procedures for assisting identified individuals who have been trafficked or are vulnerable to trafficking. Referral lists should help patients access services that meet various immediate, intermediate, and long-term needs. Referral lists also should include information about how to connect with both national and local anti-trafficking resources.
    • Be Aware of Indicators of Human Trafficking for Adults. The National Human Trafficking Training and Technical Assistance Center has developed indicators of adult human trafficking. Indicators that may arise during a telehealth visit include instances where:
      • The patient is not in control of personal identification or does not have valid identification as part of the visit
      • The patient does not know where they live (or their geolocation does not match their stated location)
      • The patient’s story does not make sense or seems scripted
      • The patient seems afraid to answer questions
      • The patient appears to be looking at an unidentified person offscreen after speaking
      • The patient’s video background appears to be an odd living or work space (may include tinted windows, security cameras, barbed wire, or people sleeping or living at worksite)
      • The patient exhibits or indicates signs of physical abuse, drug or alcohol misuse, or malnourishment.
    • Be Aware of Indicators of Human Trafficking for Children. Indicators of human trafficking for children often differ from those for adults. The National Center for Missing & Exploited Children (NCMEC) has issued a list of risk factors useful for identifying possible indicators of child sex trafficking. Although NCMEC cautions that no single indicator can accurately identify a child as a sex trafficking victim, the presence of multiple factors increases the likelihood of identifying victims. Indicators that may arise during a telehealth visit include the following:
      • The child avoids answering questions or lets others speak for them
      • The child lies about their age and identity or otherwise responds to the provider in a manner that doesn’t align with their telehealth profile or account information
      • The child appears to be looking at an unidentified person offscreen after speaking
      • The child uses prostitution-related terms, such as “daddy,” “the life,” and “the game”
      • The child has no identification (or their identification is held by another person)
      • The child displays evidence of travel in their video background (living out of suitcases, at motels, or in a car)
      • The child references traveling to cities or states that do not match their geolocation
      • The child has numerous unaddressed medical issues.

    How McDermott Can Help

    The legal landscape surrounding telehealth providers’ and online platforms’ responsibility to monitor for human trafficking is complicated. The McDermott digital health team is able to advise telehealth companies on how to navigate the patchwork of legal requirements and implement monitoring best practices to enable providers to assist trafficked patients. If you have questions about how these requirements affect your organization, please contact any of the authors of this blog post or your regular McDermott lawyer.

    Authors

    Jayda Greco

    Partner

    Chicago

    Alan LeBlang

    Associate

    Chicago

    Lisa Mazur

    Partner

    Chicago

    More insights
    Endnotes

  • End of an Era: FDA Retires 2017 Interim Policies for Bulk Drug Lists

    End of an Era: FDA Retires 2017 Interim Policies for Bulk Drug Lists

    CLIENT ALERT / US POLICY

    End of an Era: FDA Retires 2017 Interim Policies for Bulk Drug Lists

    February 3, 2025

    Read time: 6 min

    Key takeaways
    Overview

    On January 7, 2025, the US Food and Drug Administration (FDA) issued two parallel guidance documents for the Section 503A and Section 503B bulk drug lists, announcing the end of FDA’s 2017 interim policies.

    Under the new guidance, titled Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry (503A interim policy) and Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance for Industry (503B interim policy), FDA will change certain procedures related to the collection and publication of information on bulk drug substances. Specifically, FDA will no longer categorize and publish bulk substances submitted for inclusion on the 503A and 503B bulk lists to its website. FDA states that these procedures no longer serve the agency’s objective to avoid disruption in patient care.

    In depth

    Background

    Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) allow compounded drug products to be exempt from some otherwise fundamental statutory requirements – such as use labeling, or new drug application or abbreviated new drug application review – if certain conditions are met. Section 503A applies to compounding pharmacies, and Section 503B applies to registered outsourcing facilities that may prepare orders that are not patient specific. Both sections require that compounded products utilize bulk drug substances that:

    • Comply with the standards of the US Pharmacopeia or National Formulary monograph, if applicable
    • Are components of FDA-approved drugs
    • Appear on the respective bulk drug list

    See our previous On the Subject for a discussion of the requirements of Sections 503A and 503B in greater detail.

    To assist FDA in developing the 503A and 503B bulk lists, it has historically requested nominations for bulk drug substances along with supporting detailed information regarding clinical needs. Since 2013, FDA has received thousands of nominations from industry stakeholders for certain bulk substances to be included in either or both lists. Because regulatory review would necessarily take significant time and resources, stakeholders raised concerns regarding disruptions to patient care in the interim period between nomination and publication of the final lists, during which time compounding would be prohibited.

    The 2017 Interim Policies

    In 2017, to address stakeholder concerns about potential interruption to compounding services while balancing FDA’s bulk drug information requirements, the FDA issued parallel 503A and 503B interim policies. These policies allowed nominated bulk substances to be used in compounding if FDA was sufficiently reassured that the substances met safety criteria.

    The policies explained that FDA would review the current nominations on a rolling basis, categorize the nominations into one of three categories discussed below, and publish the categorization to the FDA website.

    • Category 1 – Substances Nominated for Bulks List Currently Under Evaluation
    • Category 2 – Substances Nominated for the Bulks List That Raise Significant Safety Risk
    • Category 3 – Substances Nominated for the Bulks List Without Adequate Support

    Under the 2017 interim policies, Category 1 substances were substances eligible for inclusion on the bulk lists and nominated with sufficient supporting information. Category 2 and 3 substances were potentially eligible for the lists but contained safety risks or were nominated with insufficient supporting information. FDA advised that it did not intend to take action against state-licensed pharmacies, federal facilities, or licensed physicians for compounding drug products using unapproved bulk substances in Category 1 provided all of the following conditions were met:

    • The original and all subsequent manufacturers of the bulk substance were registered under Section 510 of the FDCA
    • The bulk substance had a valid certificate of analysis
    • The compounded drug product using the bulk substance was created in compliance with all other conditions of Sections 503A and 503B.

    The 2025 Interim Policies

    The new 2025 interim policies eliminate the use of Categories 2 and 3. Bulk substance nominations submitted on or after January 7, 2025, will no longer be categorized and published to the FDA website, although FDA will continue to review nominations it receives. According to FDA, the 2017 interim policies’ categorization of nominations “no longer serves the interim [policies’] stated objective of avoiding unnecessary disruption to patient treatment.” Instead, FDA notes that nominators have had ample opportunity to provide sufficient supporting information for the placement of bulk drug substances in Category 1 since the introduction of the policies in 2017.

    FDA confirmed that bulk substances currently listed in Category 1 will continue to be afforded the enforcement discretion provided under the previous policies. Bulk substances listed in Categories 2 or 3 will not be afforded such discretion even where stakeholders update the nominations to provide sufficient information. FDA clarified that it will focus resources on finalizing the 503A and 503B bulk drug lists through rulemaking in batches.

    Analysis

    The 2025 interim policies indicate FDA’s continued focus on regulating the compounding of drugs under Sections 503A and 503B. The updated policies further indicate FDA’s intention to finalize the bulk drug lists through rulemaking, a process that has spanned almost a decade. The new interim policies should not change the current practice of compounding: Category 1 drug substances will remain generally available for compounding, but FDA reserves its authority to exercise enforcement discretion. However, stakeholders should be aware that new nominations to the bulk lists will not be afforded enforcement discretion and should not be compounded until published in the finalized bulk drug lists following their complete evaluation by FDA.

    The McDermott Difference

    McDermott will continue to monitor updates on these interim policies and any notices related to the bulk drug lists. For more information, please contact one of the authors or any other member of McDermott’s Food, Drug & Medical Device Regulatory Practice Group.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Jeff Weinstein

    Counsel

    Washington, DC

    Marissa Hill Daley

    Law Clerk

    Washington, DC

    Jae Hyun Lee

    Associate

    New York – One Vanderbilt Avenue

    Tyler Barton

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • CMS Implements First Major Updates to Lab Personnel Requirements in 30+ Years

    CMS Implements First Major Updates to Lab Personnel Requirements in 30+ Years

    ARTICLE / CLIENT ALERT

    CMS Implements First Major Updates to Lab Personnel Requirements in 30+ Years

    January 31, 2025

    Read time: 11 min

    Key takeaways
    Overview

    On December 28, 2024, a long-awaited Centers for Medicare & Medicaid Services (CMS) final rule became effective, significantly updating laboratory personnel requirements under Subpart M of the Clinical Laboratory Improvement Amendments (CLIA) for the first time since 1992. These changes affect all clinical laboratory personnel performing moderate- or high-complexity laboratory tests (i.e., nonwaived labs), from laboratory directors to those performing tests. The final rule follows the 2022 proposed rule, which generated more than 20,000 comments from clinical laboratory stakeholders. The final rule also updated CLIA regulations pertaining to proficiency testing, which we discussed in our previous On the Subject.

    In depth

    Key Updates to CLIA Personell Rules for Laboratories Performing Nonwaived Tests

    Lab Director Requirements

    A laboratory director of a nonwaived lab who holds a doctor of medicine (MD) or doctor of osteopathy (DO) degree must also be certified in anatomic pathology or clinical pathology, or both, by the American Board of Pathology or the American Osteopathic Board of Pathology. Unlike prior qualifications, board eligibility is no longer sufficient. If a physician serving as laboratory director does not hold the aforementioned board certification, they must have at least one year of experience directing or supervising nonwaived laboratory testing (two years in the case of high-complexity laboratories) and at least 20 continuing medical education or continuing education units covering clinical laboratory director responsibilities in order to qualify as a laboratory director.

    Nonphysician directors of laboratories performing high-complexity tests must have:

    • A doctoral degree in chemical, biological, clinical, or medical laboratory science or medical technology
    • At least two years of laboratory training or experience
    • At least two years of experience directing or supervising high-complexity testing
    • At least 20 continuing education hours in laboratory practice that cover director responsibilities.

    For laboratories performing moderate-complexity tests, a nonphysician director may hold a doctoral, master’s, or bachelor’s degree in the aforementioned disciplines. Qualifying doctoral degrees do not include MD, DO, doctor of podiatry, doctor of veterinary medicine, or honorary degrees. Moderate-complexity laboratory directors with a master’s or bachelor’s degree must also demonstrate at least one to two years of training and at least one to two years of supervisory experience in nonwaived laboratory testing and must obtain at least 20 continuing education credit hours in laboratory practice that cover nonwaived lab director responsibilities. Moderate-complexity laboratory directors with a doctoral degree do not have a training and supervisory experience requirement but must meet the 20 continuing education hours obligation.

    Laboratory directors may obtain the required laboratory experience through a medical residency or fellowship, or by providing services in a facility that meets the definition of a laboratory under 42 CFR § 493.2 (i.e., excluding facilities that only collect, prepare, or courier specimens without performing testing). Experience at forensic labs, research labs that test but do not report patient test results, and drug testing labs certified by the Substance Abuse and Mental Health Services Administration do not meet this requirement.

    Finally, as a new requirement, nonwaived lab directors must be onsite at least once every six months, with an interval of at least four months between the two annual onsite visits.

    • What’s the impact? The final rule emphasizes the need for lab directors to either earn advanced degrees or demonstrate specific experience in clinical laboratory settings. Directors serving remote labs also must be onsite at least twice a year.

    Educational Qualifications

    Under prior nonwaived laboratory director qualification standards, individuals with a degree in a physical science could qualify for various laboratory positions. However, under the new rule, CMS eliminated the physical science degree as an acceptable qualification for positions requiring a bachelor’s degree. CMS did not define “physical science degree” but instead stated that it now recognizes only degrees in biological or chemical sciences, or in clinical or medical laboratory technology.

    • What’s the impact? Individuals with a physical science degree or otherwise lacking a qualifying degree must meet additional educational requirements to perform testing services and hold supervisory roles in nonwaived laboratories. Instead of automatic qualification based on a degree, qualification will be determined based on an “educational algorithm” that evaluates completion of required courses in laboratory science.
    • Are any individuals eligible for grandfathering? Individuals who were already employed in qualifying positions as of December 28, 2024, will be “grandfathered in” and will not need to meet the new educational requirements as long as they remain employed without interruption.

    Requirement that Nurses Obtain Additional Training for High-Complexity Testing

    One of the most debated aspects of the proposed rule was whether individuals with a bachelor of science in nursing (BSN) should be allowed to perform high-complexity testing. CMS initially proposed to allow BSN holders to perform high-complexity tests without additional training; however, after receiving more than 19,000 comments in opposition via a form letter, CMS changed course. The agency concluded that nursing education, while extensive in clinical training, does not provide sufficient depth in laboratory science concepts, such as quality control and proficiency testing, which are crucial for high-complexity tests.

    • What does this mean for nurses? Nurses holding a BSN can still perform high-complexity testing, but only if they complete additional training, such as coursework in biological or chemical sciences and clinical lab science, equivalent to what is required for an associate degree in laboratory science or medical technology.

    New Pathway for Technical Consultant Qualifications

    Historically, CLIA rules allowed a laboratory director or technical supervisor to delegate performance of competency assessments for high-complexity test personnel to a general supervisor. However, CLIA rules also historically required that a technical consultant perform competency assessments, without delegation, for moderate-complexity test personnel. This meant that an individual with an associate degree – the minimum education requirement for general supervisors – was permitted to perform high-complexity competency assessments, but that same individual could not perform moderate-complexity competency assessments. Thus, the education requirements for individuals performing competency assessments on high-complexity personnel, which could be delegated to a person with an associate’s degree, were less stringent than for moderate-complexity personnel competency assessments, because a technical consultant must have at least a bachelor’s degree in a qualifying field of study.

    Under the new rule, CMS created a route for individuals with an associate degree in laboratory science or medical technology plus four years of clinical training or experience to qualify as technical consultants for moderate-complexity testing. This change expands the pool of qualified professionals able to perform competency assessments in both moderate- and high-complexity settings.

    • What does this mean for technical consultants? Most technical consultants will now be able to perform competency assessments on all laboratory personnel, for both moderate- and high-complexity testing. However, the qualifications for blood gas analysis (which measures the levels of oxygen and carbon dioxide in the blood) remain more stringent. To qualify as a technical consultant for blood gas analysis, an individual must have a bachelor’s degree in laboratory science, respiratory therapy, or a related field, plus additional training in blood gas analysis.

    Permanent Qualification for Military-Trained Laboratory Technicians as Testing Personnel

    The final rule solidifies a permanent pathway for individuals to qualify as testing personnel in moderate- and high-complexity laboratories if they have completed a medical laboratory procedures course of at least 50 weeks and have held the military enlisted occupational specialty of medical laboratory specialist (laboratory technician). Previously, military laboratory specialists/laboratory technicians could only qualify for high-complexity testing if they were grandfathered in before 1995.

    • What does this mean for military personnel? Military-trained laboratory personnel will now be able to perform moderate- and high-complexity testing without being subject to a grandfathering provision, allowing more veterans to enter civilian laboratory roles.

    Expanded Definition for Midlevel Practitioner

    CMS expanded the “midlevel practitioner” definition to include nurse anesthetists and clinical nurse specialists. Previously, this definition was limited to nurse midwives, nurse practitioners, and physician assistants. In each case, the individual must be licensed by the state in which they practice, if such licensing is required.

    • What’s the impact? A laboratory holding a CLIA certificate for provider-performed microscopy may have a director or testing personnel who is a licensed midlevel practitioner. As we continue to see a shortage of healthcare professionals, the expanded definition for midlevel practitioners will permit a larger and more diverse group of professionals serve in these positions.

    Impact on Lab Staffing and the Future

    As laboratories increasingly integrate technology such as artificial intelligence and automation into their workflows to address staffing shortages, they will need professionals who are not only equipped to adapt to new technologies but also accustomed to traditional testing methods. Clinical laboratories have experienced the same workforce shortages, burnout, and job satisfaction challenges as other sectors of the healthcare industry. The final rule’s changes hopefully will strike a balance between addressing staffing shortages by expanding qualification standards for certain roles and protecting patient safety and ensuring sufficient scientific expertise by limiting those who can serve in supervisory roles such as lab directors.

    For more information on clinical laboratory personnel and operation requirements, please contact Greg Fosheim or Ashley Ogedegbe.

    Position CLIA Complexity Level Degree Required Qualification Pathways
    Moderate
    Laboratory Director Moderate and High Complexity

    High: Doctoral degree (MD, DO, DPM or PhD) in relevant field

    Moderate: Bachelor’s degree in a relevant field

    Path 1: Medical doctor (MD/DO) with pathology certification
    • Licensed MD or DO in the state
    • Certified in anatomic or clinical pathology (or both) by the American Board of Pathology or the American Osteopathic Board of Pathology
    Path 2: Medical doctor (MD/DO/DPM) with experience
    • Licensed MD, DO, or DPM in the state
    • Laboratory experience:
      • One year directing or supervising nonwaived testing
      • 20 continuing education (CE) credit hours covering director responsibilities
    Path 3: Doctoral degree in science field
    • Earned doctoral degree in relevant field (e.g., biology, chemistry, CLS, MLS, or MT)
    • Coursework or research project in related field
    • 20 CE credit hours covering director responsibilities
    • Certified by a US Department of Health and Human Services-approved board
    • One year experience directing/supervising nonwaived testing
    Path 4: Master’s degree in science field
    • Earned master’s degree in relevant field
    • Laboratory experience:
      • One year training/experience in nonwaived testing
      • One year supervisory experience in nonwaived testing
    • 20 CE credit hours covering director responsibilities
    Path 5: Bachelor’s degree in science field
    • Earned bachelor’s degree in chemistry, biology, or medical laboratory science or medical laboratory technology in any combination or equivalent with required coursework:
      • 48 semester hours in MLS/MLT or science courses
      • 12 hours each in chemistry and biology, and 24 semester hours of chemistry, biology, or medical laboratory science or medical laboratory technology in any combination (specific topics required)
    • Laboratory experience:
      • Two years training/experience in nonwaived testing
      • Two years supervisory experience in nonwaived testing
    • 20 CE credit hours covering director responsibilities
    High
    High-complexity path See Paths 1 – 3 above. For the subspecialty of oral pathology, certification by the American Board of Oral Pathology, American Board of Pathology, or the American Osteopathic Board of Pathology is also required.
    Grandfather clause (applies to moderate and high) Individuals qualified and serving as a lab director of moderate-complexity testing as of December 28, 2024, and continuously since then, are considered qualified.
    Technical Supervisor High Complexity Bachelor’s in chemical, physical, biological, clinical lab science, or medical technology
    • Four years of lab experience (for bachelor’s holders)
    • Master’s with two years of experience
    • Doctoral degree with one year of experience
    Technical Consultant Path 1: MD/DO with pathology certification
    • Licensed MD or DO in the state
    • Certified in anatomic or clinical pathology (or both) by the American Board of Pathology or the American Osteopathic Board of Pathology
    Path 2: MD/DO/DPM with experience
    • Licensed MD, DO, or DPM in the state
    • At least one year of laboratory training or experience in nonwaived testing in designated specialties
    Path 3: Doctoral/master’s degree in science field
    • Earned doctoral or master’s degree in relevant field (e.g., biology, chemistry, or medical technology)
    • At least one year of laboratory training or experience in nonwaived testing in designated specialties
    Path 4: Bachelor’s degree in science field
    • Earned bachelor’s degree in relevant field (e.g., biology, chemistry, or medical technology)
    • At least two years of laboratory training or experience in nonwaived testing in designated specialties
    Path 5: Associate degree in science field
    • Earned associate degree in medical laboratory technology or related field
    • At least four years of laboratory training or experience in nonwaived testing in designated specialties
    Path 6: Blood gas analysis qualification
    • Meet qualifications under Path 1, 2, 3, or 4
    • Alternatively, bachelor’s degree in respiratory therapy or cardiovascular technology and two years of experience in blood gas analysis
    Grandfather clause Individuals qualified and serving as a technical consultant for moderate-complexity testing as of December 28, 2024, and continuously since then, are considered qualified.
    Clinical Consultant Moderate and High Complexity

    High: MD, DO, or doctoral degree in a related science field (see lab director paths 1 – 3 and 5 above)

    Moderate: MD, DO, or doctoral degree in a related science field (see lab director paths 1 – 3 above)

    • Licensed to practice medicine or PhD in a relevant field
    • Board certification (if applicable)
    General Supervisor High Complexity Bachelor’s degree in chemical, physical, biological, or clinical lab science or medical technology
    • One year of experience in high-complexity testing
    • Associate degree with specified training and experience in specialties
    Testing Personnel Moderate and High Complexity

    High: Associate degree in laboratory science or medical lab technology

    Moderate: High school diploma or equivalent, or associate/bachelor’s degree in relevant field

    High
    • Bachelor’s degree in relevant field
    • Education/training equivalent to an associate degree plus experience
    • Military training in laboratory procedures
    Moderate
    • On-the-job training and competency assessment
    • Military or vocational training in laboratory procedures
    Authors
    More insights

  • Receiving Debt-Financed Distributions From a QOF: IRS Allows Significant Flexibility (And Some Traps)

    Receiving Debt-Financed Distributions From a QOF: IRS Allows Significant Flexibility (And Some Traps)

    ARTICLE / CLIENT ALERT

    Receiving Debt-Financed Distributions From a QOF: IRS Allows Significant Flexibility (And Some Traps)

    January 31, 2025

    Read time: 7 min

    Key takeaways
    Overview

    Qualified Opportunity Funds (QOFs) offer generous tax incentives but are bound by a complicated set of rules, not to mention the complexity of Subchapter K of the Internal Revenue Code (IRC), as QOFs are typically organized as partnerships for tax purposes.

    A common misconception among tax practitioners is the belief that debt-financed distributions from QOFs within two years of funding are prohibited. Many cite Internal Revenue Service (IRS) regulations and accompanying guidance as justification for this view, claiming such distributions trigger a “disguised sale,” thereby nullifying the tax benefits of the QOF. However, while regulations exist that could impact debt-financed distributions in limited circumstances, the foundational disguised sale rules – well-established in US tax code for decades – remain unchanged.

    In depth

    The Benefits of Investing in QOFs

    Before diving deeper, let’s explore the compelling benefits of investing in a QOF by making a “qualifying investment”:

    • Deferral of Capital Gains: If you reinvest capital gains from the sale of assets (like real estate or stocks) into a QOF within 180 days, you can defer paying federal capital gains tax until your tax year, including December 31, 2026.
    • Tax Reduction: Investments made before December 31, 2021, can reduce your capital gains tax by 10% upon recognition, and those made before December 31, 2019, can see a reduction of 15%.
    • Permanent Exclusion: Perhaps the most attractive benefit, by holding your investment in a QOF for 10 years or more, you can permanently exclude any gains from federal taxes, including depreciation recapture.

    The Risks of Debt-Financed Distributions

    Despite these enticing benefits, caution is essential. Engaging in debt-financed distributions to achieve liquidity can lead to significant tax consequences. When an investor contributes eligible gains to a QOF, the investor’s initial tax basis in that investment is zero. Any cash distribution exceeding this zero basis could trigger detrimental outcomes, including the loss of QOF benefits and immediate taxation on deferred gains.

    However, certain events can increase a partner’s tax basis in a QOF. For example, when deferred gains are recognized on December 31, 2026, the partner’s basis increases by the amount of the eligible gain contributed. Additionally, debt incurred by the QOF can be allocated to partners, potentially allowing them to receive cash without jeopardizing QOF benefits.

    Partnership interest tax basis reflects the amount the partner has invested, adjusted for various factors such as additional contributions, distributions, and share of partnership debt. It is important because it determines the extent to which distributions can be taken tax-free and helps calculate any gain or loss when the partner disposes of their partnership interest.

    When a QOF incurs nonrecourse debt, that debt is typically allocated among the partners according to their ownership interests under IRC Section 752. This allocation increases the outside basis for each partner by the amount of debt allocated to them. For example, if a QOF takes on a $1 million loan and a partner has a 50% interest, that partner’s outside basis typically will increase by $500,000.

    Debt-financed distributions occur when a QOF distributes cash or property to its partners that is funded by such borrowed money. Because the partner’s share of the debt increases their outside basis, these distributions can often be received by the partner without triggering a taxable event.

    For instance, if a partner initially contributes $100,000 of eligible gain in cash to a QOF, their outside basis will start at zero. If the QOF subsequently incurs debt of $200,000 and allocates $100,000 of that debt to the partner, their outside basis will increase to $100,000. If the partner then receives a distribution of $80,000, the receipt of the distribution may not be taxable because it does not exceed the partner’s adjusted basis.

    Now, let’s clarify the regulations surrounding debt-financed distributions. A disguised sale occurs when transactions that are ostensibly a contribution followed by a distribution are treated by the IRS as a sale for tax purposes. Under Treas. Reg. § 1.707-3, if a distribution occurs within two years of contributing “other property” (non-cash property), it may be presumed to be a disguised sale. However, cash contributions do not fall into the “other property” category and are treated differently. Therefore, when cash is the property contributed to a QOF, there is no straightforward “disguised sale” issue. Additionally, Treas. Reg. § 1.707-5(b) includes rules for avoiding disguised sale treatment for debt-financed distributions.

    Yet, caution is still warranted. The QOF must navigate “inclusion event” rules carefully. If a distribution’s fair market value exceeds a partner’s outside basis, this triggers an inclusion event, leading to negative tax implications. However, if a distribution is debt-financed, the allocation of debt can instantaneously increase a partner’s basis, mitigating some risks.

    Understanding the Disguised Sale “Supercharge Rule”

    The disguised sale “supercharge rule” (Treas. Reg. § 1.1400Z2(a)-1(c)(6)(iii)(A)(2)) is a complex but crucial component of the regulations surrounding QOFs. This rule highlights how contributions to a QOF can be impacted by how those contributions are characterized under the tax law.

    Generally, under Treas. Reg. § 1.1400Z2(a)-1 (the “deferral regulation”), the amount of capital gain that is eligible for deferral is subject to a special rule for QOF partnerships. The regulations stipulate that, to the extent a transfer would be characterized as other than a contribution (citing an IRC Section 707 disguised sale as an example), the transfer is not treated as made in exchange for a qualifying investment under Treas. Reg. § 1.1400Z2(a)-1(c)(6)(iii)(A)(1). In other words, if a QOF member made a contribution that was recast as a disguised sale, the QOF interest that the member took in exchange is not a qualifying investment and is not entitled to the tax benefits described above. The regulations go further in the supercharge rule and say that if any transfer to the QOF is not treated as a contribution, in whole or part, then the portion of the transfer to the partnership that is not recharacterized will not be a qualifying investment to the extent that it would have been characterized if the disguised sale under Section 707 were broadened by making the following two “supercharging” modifications:

    • Any cash contributed is treated as “other property”
    • In the case of a debt-financed distribution, the partner’s share of liabilities under Section 752 is treated as zero.

    This second modification eliminates the benefits of a debt-financed distribution but only if the supercharge rule is initially triggered.

    Therefore, even a small, disguised sale can lead to a big problem, because the remaining contribution is subject to the disguised sale supercharge rule. However, if no part of a contribution is recast as a disguised sale under the general tax rules, then the supercharge rule is not implicated. Even though debt-financed distributions are not necessarily part of a disguised sale, many tax practitioners think that any debt-financed distribution made within the two-year presumption period is prohibited.

    In our view, this interpretation is overly conservative, providing an unnecessary impediment to liquidity from QOF investments. Investors seeking liquidity should instead apply the traditional disguised sale analysis before deciding whether to proceed with a debt-financed distribution.

    Conclusion

    Navigating the complexities of QOFs requires careful attention to detail, particularly regarding debt-financed distributions and outside basis calculations. While the benefits of investing in QOFs are substantial, a thorough understanding of the associated regulations and potential pitfalls is essential for maximizing those benefits. By staying informed and seeking relevant guidance, investors can protect their interests and leverage the unique opportunities presented by QOFs.

    If you have questions or need assistance navigating the complexities surrounding claiming debt-financed distributions from QOFs, please contact your regular McDermott lawyer or one of the authors of this article.

    Authors

    David D. Sherwood

    Counsel

    Washington, DC

    More insights